Kenneth Altman, MD
Otolaryngology · Danville, PANPI 1518927409
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (57.2%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. Merck accounts for 95.7% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2021 at $5,793 and has fallen 96.2% since, to $219 in 2025.
Across 14 payments — averaging $442.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$6K
- GSK$117
- Tactile Systems Technology Inc$39
- Regeneron Healthcare Solutions, Inc.$28
- Ambu Inc.$28
- Olympus America Inc.$28
- plus $26 from 1 others
Across 18 payments — averaging $5346.72 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$96K
What the payments were for
- Consulting fees$2,25036%
- Speaking & faculty fees$3,54357%
- Food & beverage$3986%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 5 | $5,925 |
| GSK | 3 | $117 |
| Tactile Systems Technology Inc | 2 | $39 |
| Regeneron Healthcare Solutions, Inc. | 1 | $28 |
| Ambu Inc. | 1 | $28 |
| Olympus America Inc. | 1 | $28 |
| Atos Medical Inc | 1 | $26 |
How this compares
$6,191 in reported general payments places this provider in the 85th percentile of 456 otolaryngology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Azelastine Hcl | 144 | $3,828 |
| Mometasone Furoate | 24 | $3,495 |
| Omeprazole | 147 | $2,374 |
| Fluticasone Propionate | 133 | $2,028 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 11 | $781 |
| Pantoprazole Sodium | 86 | $780 |
| Famotidine | 77 | $757 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 18 | $268 |
| Gabapentin | 26 | $245 |
| Amitriptyline Hcl | 11 | $16 |
Paid to pharmacies, not to this prescriber.
Other otolaryngology in Danville
- Nancy SnydermanPhiladelphia$4.5M
- David YenBethlehem$1.4M
- David KennedyPhiladelphia$603K
- Stella LeePittsburgh$438K
- James PalmerPhiladelphia$331K
- Ryan SooseSeven Fields$134K
- Mathew NagorskyPhiladelphia$95K
- Noam CohenPhiladelphia$76K
- Nithin AdappaPhiladelphia$72K
- Matthew SpectorPittsburgh$56K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.